Tag: David Hoey
Vaxxas hits enrollment target in trial of HD-MAP technology for pandemic response
Australian biotechnology company Vaxxas has completed enrollment for its largest clinical trial to date, testing the safety and immune response of its high-density microarray patch (HD-MAP) for vaccine delivery.
Vaxxas secures $2M grant from BARDA to develop needle-free mRNA vaccines
Vaxxas, a clinical-stage biotechnology company specializing in high-density microarray patch (HD-MAP) vaccine delivery, has been awarded a $2 million (AUD 3.2 million) grant as a Concept Stage winner in the United States Biomedical Advanced Research and Development Authority’s (BARDA) $50 million Patch Forward Prize.
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Vaxxas’ new needle-free vaccine manufacturing plant opens in Queensland
Biotechnology company Vaxxas has completed work on its new needle-free vaccine technology manufacturing facility in Northshore Hamilton.
Vaxxas’ needle-free seasonal influenza vaccine enters clinical trial
Vaxxas has commenced the Phase I clinical trial of the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate via its proprietary high-density microarray patch (HD-MAP) technology.
Vaxxas kickstarts needle-free COVID-19 vaccine clinical trial
Australian biotechnology company Vaxxas has begun the Phase I clinical trial of the first needle-free COVID-19 vaccine candidate.
Featured Article
Data-rich or data-poor: Where should manufacturers focus their AI efforts?
Over the past year, manufacturers worldwide have made significant strides in adopting artificial intelligence technologies, moving beyond the initial hype to tangible implementations that deliver real business value.
